Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingchang suppository (also known as Qing-Chang-Shuan or QCS) is a Traditional Chinese Medicine (TCM) preparation developed by Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically formulated for the treatment of mild to moderate active ulcerative proctitis, particularly for patients presenting with the 'damp-heat syndrome of the large intestine' according to TCM diagnostics. The formulation is a multi-herbal combination typically containing *Indigo naturalis* (Qingdai), *Radix Sanguisorbae* (Diyu), *Coptis chinensis* (Huanglian), *Phellodendron amurense* (Huangbai), and *Galla Chinensis* (Wubeizi). Its therapeutic effects are attributed to its anti-inflammatory and mucosal healing properties, which involve the inhibition of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6, as well as the modulation of the intestinal immune response and gut microbiota.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingchang suppository (04656b).